Coronary artery bypass grafting for triple vessel disease in cardiac amyloidosis.

MedStar author(s):
Citation: BMJ Case Reports. 16(9), 2023 Sep 12.PMID: 37699742Institution: MedStar Union Memorial Hospital | MedStar Washington Hospital CenterDepartment: Hospitalist J | Internal Medicine Residency | PathologyForm of publication: Journal ArticleMedline article type(s): Case Reports | Journal ArticleSubject headings: *Amyloidosis | *Coronary Artery Disease | *Heart Failure, Systolic | Amyloidosis/co [Complications] | Amyloidosis/su [Surgery] | Coronary Artery Bypass | Coronary Artery Disease/co [Complications] | Coronary Artery Disease/su [Surgery] | Humans | Immunoglobulin Light Chains | Year: 2023ISSN:
  • 1757-790X
Name of journal: BMJ case reportsAbstract: Cardiac amyloidosis is a rare condition with an estimated incidence of 18-55 per 100 000 person-years. It is associated with either immunoglobulin light chain (AL) or transthyretin amyloid (ATTR), both of which result in a restrictive cardiomyopathy complicated initially by diastolic dysfunction and subsequently followed by biventricular systolic heart failure. Untreated cardiac amyloidosis carries an extremely poor prognosis with an estimated median survival time of less than 1 year in AL and 4 years in ATTR amyloidosis. This is the sixth described report of coronary artery bypass grafting in patients with underlying cardiac amyloidosis. Copyright © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.All authors: Acharya I, Liang JJ, Haas CJFiscal year: FY2024Digital Object Identifier: Date added to catalog: 2023-11-22
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 37699742 Available 37699742

Cardiac amyloidosis is a rare condition with an estimated incidence of 18-55 per 100 000 person-years. It is associated with either immunoglobulin light chain (AL) or transthyretin amyloid (ATTR), both of which result in a restrictive cardiomyopathy complicated initially by diastolic dysfunction and subsequently followed by biventricular systolic heart failure. Untreated cardiac amyloidosis carries an extremely poor prognosis with an estimated median survival time of less than 1 year in AL and 4 years in ATTR amyloidosis. This is the sixth described report of coronary artery bypass grafting in patients with underlying cardiac amyloidosis. Copyright © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.

English

Powered by Koha